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Abstract
Background: The artemisinin-based combination treatment (ACT) of dihydroartemisinin (DHA) and piperaquine (PQP) is a
promising novel anti-malarial drug effective against multi-drug resistant falciparum malaria. The aim of this study was to
show non-inferiority of DHA/PQP vs. artesunate-mefloquine (AS+MQ) in Asia.
Methods and Findings: This was an open-label, randomised, non-inferiority, 63-day follow-up study conducted in Thailand,
Laos and India. Patients aged 3 months to 65 years with Plasmodium falciparum mono-infection or mixed infection were
randomised with an allocation ratio of 2:1 to a fixed-dose DHA/PQP combination tablet (adults: 40 mg/160 mg; children:
20 mg/320 mg; n=769) or loose combination of AS+MQ (AS: 50 mg, MQ: 250 mg; n=381). The cumulative doses of study
treatment over the 3 days were of about 6.75 mg/kg of DHA and 54 mg/kg of PQP and about 12 mg/kg of AS and 25 mg/kg of
MQ. Doses were rounded up to the nearest half tablet. The primary endpoint was day-63 polymerase chain reaction (PCR)
genotype-corrected cure rate. Results were 87.9% for DHA/PQP and 86.6% for AS+MQ in the intention-to-treat (ITT; 97.5% one-
sided confidence interval, CI: .22.87%), and 98.7% and 97.0%, respectively, in the per protocol population (97.5%
CI:.20.39%).Nocountryeffectwasobserved.Kaplan-Meier estimatesof proportionsofpatientswithnewinfectionsonday63
(secondary endpoint) were significantly lower for DHA/PQP than AS+MQ: 22.7% versus 30.3% (p=0.0042; ITT). Overall
gametocyteprevalence (days 7 to63; secondary endpoint), measuredas person-gametocyte-weeks, was significantly higher for
DHA/PQP than AS+MQ (10.15% versus 4.88%; p=0.003; ITT). Fifteen serious adverse events were reported, 12 (1.6%) in DHA/
PQP and three (0.8%) in AS+MQ, among which six (0.8%) were considered related to DHA/PQP and three (0.8%) to AS+MQ.
Conclusions: DHA/PQP was a highly efficacious drug for P. falciparum malaria in areas where multidrug parasites are
prevalent. The DHA/PQP combination can play an important role in the first-line treatment of uncomplicated falciparum
malaria.
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The bisquinoline piperaquine (PQP) was first synthesised in the
1960s independently by teams in China and France. In 1978,
because of its greater potency and tolerability relative to
chloroquine, PQP replaced chloroquine in the Chinese National
Malaria Control Programme. Such was the success of the
programme, that the following decade saw the use of PQP decrease
because of the decrease in patients suffering from malaria.
In 1990, Chinese scientists working to develop alternative anti-
malarial treatments that might offer higher cure rates with better
tolerability profiles included PQP phosphate in an artemisinin-
based combination treatment (ACT), known as China-Vietnam 4
(CV4H), that also included dihydroartemisinin (DHA), trimetho-
prim and primaquine phosphate [1,2]. During the development
programme [3], doses of each component of the combination were
modified resulting in a new formulation, CV8H, which was tested
in Vietnam [4,5] and administered in the Vietnamese Malaria
Control Programme in 2000. This programme was widely
successful despite the presence of chloroquine resistance in
Vietnam [6]. However, concerns about the association of red cell
haemolysis with primaquine in populations with glucose-6-
phosphate dehydrogenase deficiency [7] and the questionable
anti-malarial potency of trimethoprim led to the removal of these
two components of the drug combination in CV8H. The
remaining two components of the regimen, the artemisinin
DHA and PQP (ArtekinH), provide a combination that is relatively
inexpensive and has been shown to be effective both in curing
malaria and preventing re-infection [2,8–12].
Since their introduction in the 1990s, ACTs have been found to be
highly effective treatments for malaria [13]. Across Asia, Africa and
South America, clinical and parasitological responses to the
combination of DHA and PQP have generally exceeded the 95%
value that the World Health Organization (WHO) recommend for
anti-malarial treatments [14]. However, in recent years there have
been suggestions that the overall efficacy of ACTs in Thailand and
Cambodia may be declining. Evidence of falling efficacy has been
characterised by reductions in the proportions of patients clearing
their parasitaemia by day 2 of treatment in the Thailand-Myanmar
border region [15,16], and by reductions in polymerase chain reaction
(PCR)-corrected cure rates at 28- and 42-day follow-up assessments in
the Cambodia-Thailand border region [17]. Relatively low cure rates
were also reported from Papua New Guinea [18] and, most recently,
there has been evidence of reduced artesunate susceptibility in
Western Cambodia [19,20]. Historically, anti-malarial drug resistance
has spread westwards from Cambodia through South Asia to Africa
[21]. Consequently, the recent reports of potential resistance to
artemisinins alone and ACTs are of great concern.
In order to assess the safety and efficacy of the treatment
combination of DHA and PQP in Asia, we conducted a
randomised trial in Thailand, Laos and India comparing DHA/
PQP with another ACT, artesunate (AS) plus mefloquine (MQ).
All study sites were located in areas of notable chloroquine
resistance. Dihydroartemisinin plus PQP was administered as a
single tablet (DHA/PQP) and AS plus MQ were administered as
separate loose tablets (AS+MQ). This study had the largest sample
size to date of any study assessing DHA/PQP in South East Asia.
Methods
The protocol and amendments for this trial and supporting
CONSORT checklist are available as supporting information; see
Protocol S1 to S8 and Checklist S1.
Study regions
This study was conducted in six centres in Thailand (Hospital
for Tropical Diseases, Faculty of Tropical Medicine, Mahidol
University, Bangkok; Suanphung Hospital, Ratchaburi; Proppra
Hospital, Proppra District, Tak; Shoklo Malaria Research Unit,
Mae Sod District, Tak; Mae Sod Hospital, Muang District, Tak;
and Mae Ramat Hospital, Mae Ramat District, Tak), two centres
in Laos (Phalanxay District Hospital, Savannakhet Province;
Xepon District Hospital, Savannakhet Province) and three centres
in India (Down Town Hospital, Guwahati, Assam; Goa Medical
College and Hospital, Goa; and Wenlock District Government
Hospital, Mangalore) over two malaria seasons, with patients
screened from June 2005 to February 2007.
The study regions provided a range of transmission conditions
and standard treatments. Study regions in Thailand were located
in malarious forest on the Thai-Myanmar border in regions of
unstable, low and seasonal malaria transmission that used
AS+MQ as a first-line treatment. Nearly all infections with
Plasmodium falciparum and P. vivax in the region are symptomatic
and P. falciparum is multi-drug resistant, with high levels of
resistance to chloroquine [22,23]. Malaria transmission in the
Phalanxay and Xepon districts in Laos was seasonal with a peak
just after the heavy rainy months of July to August. Previous
studies in the Phalanxay district showed high levels of chloroquine
resistance [24,25]. The first-line treatment was artemether/
lumefantrine. In India, study regions included areas of perennial
transmission (Assam), perennial transmission with a seasonal peak
from June to September (Goa), and transmission active in post-
monsoon months (Mangalore). Chloroquine resistance was present
at all study sites, with site records showing 28-day treatment failure
rates of 32% in Assam (in 2002), 54% in Goa (in 2007) and 67% in
Mangalore City (in 2005). Artemisinin-based combination treat-
ments are used as standard treatments in Goa, Mangalore and
Assam (specifically AS plus sulphadoxine/pyrimethamine).
Patients
Males and females aged from 3 months to 65 years weighing at
least 5 kg with fever or history of fever ($37.5uC) and
microscopically confirmed mono-infection with P. falciparum
(asexual forms parasitaemia $80 per mL #200,000 per mL) or
mixed infection were eligible for the study. Local regulations were
followed in India that required all recruited patients to be aged 18
years and over. Key exclusion criteria were: severe malaria,
treatment with MQ in the 60 days prior to screening, treatment
with DHA/PQP in the 3 months prior to screening and .4%
parasitised red blood cells. Pregnant or lactating women were not
eligible for the study.
Study design
This was a randomised, Phase III, open-label study with two
treatment arms: DHA/PQP and the active comparator AS+MQ.
At the time the study was designed, there was no single first line
treatment in the countries involved in the study. However,
AS+MQ was first line treatment in Thailand, was well
characterized and was widely used in all the considered countries.
This made AS+MQ suitable as the control treatment against
which the efficacy and safety of DHA/PQP would be tested. As
the study was not blinded, to limit bias, the following procedures
were put in place: 1) Randomisation was conducted under blinded
conditions: the blind to the investigator and patient in the
randomisation process was maintained by the use of sealed
envelopes. 2) Evaluation of the PCR test results was blinded
(centralised at the Prince Leopold Institute of Tropical Medicine,
Antwerp, Belgium, with quality control at Shoklo Malaria
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statistician of the independent Data Monitoring Committee
reviewed the most relevant safety data and participated in the
final blinded data review meeting where all decisions about
assessment of the primary outcome and patient allocation to the
pre-defined populations were made under blinded conditions. The
randomisation list was generated by an external contract research
organisation (MDS Pharma Services) using the plan procedure of
SAS (Cary, NC, USA). Patients were allocated to receive either
DHA/PQP or AS+MQ following a 2:1 randomisation schedule
ratio. The unbalanced ratio was chosen to increase the chance of
detecting rare adverse reactions and to provide more precise
estimates of cure rates in the DHA/PQP arm.
Dihydroartemisinin/PQP (Eurartesim
TM, Sigma-Tau, Italy)
was given once daily, on days 0, 1 and 2 of the study, at the
standard dosage of 2.25 mg/kg and 18 mg/kg per dose of DHA
and PQP, respectively, rounded up to the nearest half tablet. To
facilitate the correct dosing of DHA/PQP, two formulations were
used (DHA 20 mg + PQP 160 mg and DHA 40 mg + PQP
320 mg). Over the 3 days, the cumulative doses were of about
6.75 mg/kg of DHA and 54 mg/kg of PQP. Artesunate and MQ
(Mepha Ltd, Switzerland) were administered as separate tablets
containing AS 50 mg and MQ 250 mg; AS was administered at
24-h intervals on days 0, 1 and 2 with a daily dose of 4 mg/kg and
MQ was administered at 15 mg/kg on day 1 and 10 mg/kg on
day 2 at 24-h intervals, but was not administered on day 0.
As part of their routine treatment, febrile patients who attended
the study centres underwent a thick blood smear test for malaria
before any anti-malarial treatment was administered. If the smear
was found to be positive for P. falciparum, patients were told about
the study and offered the opportunity to participate. Eligible
patients who agreed to participate were given detailed explana-
tions of the trial from study staff, including the information that
they would be given one of two different anti-malaria treatments
on a random basis. Participating patients all provided written
informed consent. Patients who declined to participate were
provided with treatment for uncomplicated P. falciparum malaria,
standard for the area in which they lived. Participating patients
were managed as outpatients and doses were given under medical
supervision, although at some centres patients could be hospital-
ised according to local practice, which ranged from 3 days at Mae
Ramat Hospital, Thailand and at centres in Laos and India to 28
days at Mahidol University, Thailand. If not in hospital, patients
were encouraged to return to the study centre for assessments on
days 1, 2, 3, 7, 14, 21, 28, 35, 42, 49, 56 and 63, and they were
also told that they could make unscheduled visits on any day on
which they felt unwell. Patients were followed-up for 63 days.
In accordance with WHO (WHO 2003 and 2009) and standard
practice in malaria clinical trials, the primary endpoint of the study
was the PCR-corrected cure rate, based on the adequate clinical
and parasitological response (ACPR), which was defined as the
absence of parasitaemia irrespective of the patient’s body
temperature, with the patient not meeting any of the pre-defined
criteria of early treatment failure or late clinical or parasitological
failure (see below). In more detail, the primary endpoint was
defined using two methods. The first method was based purely on
the standard definitions of early/late clinical and parasitological
failure as defined by the WHO [26]. This endpoint is referred to as
the true treatment failure and is defined as the sum of early
treatment failures and late recrudescences, which included late
treatment failures that were assessed as recrudescences according
to PCR analysis (100 minus the true treatment failure rate
provides the WHO cure rate). The second method, agreed with
the Data Monitoring and the Clinical Development Committees,
was based on a pre-defined procedure that expanded the WHO
definitions with a set of rules allowing the evaluation of each
individually randomised patient (for definitions see Table 1). This
approach was considered to be primary because it was deemed to
be in line with the requirements of the most stringent regulatory
authorities. All cases not strictly matching the WHO definitions
and/or the described procedure were reviewed individually at the
final blinded data review meeting. Day 63 was chosen as the
primary time-point because of the long half lives of piperaquine
and mefloquine and because the risk of new infection is lower than
in other parts of the world.
Secondary endpoints included PCR-corrected adequate clinical
and parasitological response on days 28 and 42, PCR-uncorrected
adequate clinical and parasitological response (PCR-uncorrected),
proportion of patients with early and late treatment failure,
proportion of aparasitaemic patients, proportion of afebrile
patients, number of new infections, gametocyte carriage and the
safety profile of the two treatments including adverse events and
12-lead electrocardiograph parameters (QT interval corrected
according to the methods of Bazett, QTc(B), and Fridericia,
QTc(F)).
Procedures
The presence of P. falciparum was verified at all study visits
including screening, using thick and thin Giemsa-stained blood
smears obtained from the patient to calculate parasite density,
which was initially calculated by counting the number of asexual
parasites per 500 leukocytes in the thick blood film, based on an
assumed white cell count of 8,000 cells per mL. Blood smears were
obtained from a finger prick applied directly to a microscope slide
to create the blood film. Parasite density per mL was calculated as:
(number of parasites counted 68,000)/(number of leukocytes
counted). For samples with higher levels of parasitaemia (.3
parasites/1000 red blood cells), parasite density was calculated
from the thin film per 1000 red blood cells as: (number of P.
falciparum trophozoites per 1000 red blood cells x haematocrit
6125.6). Gametocyte prevalence was also evaluated. Both the
thick and thin blood smear readings were done locally following
the above described procedure, while the gametocyte assessments
were carried out in accordance with standard practice at each
individual site. All technicians who read the slides had undergone
appropriate training in malaria-related microscopy and had at
least 5 years experience in reading blood smears. A process of
quality control was used to monitor the values being provided by
the local laboratories. One in five of every samples was sent to a
central, independent laboratory (Department of Parasitology and
Medical Entomology, Muhimbili University of Health and Allied
Sciences, Dar Es Salaam, Tanzania) for review.
Three spots of blood were collected on 3MM filter paper
(Whatman, UK) at the enrolment visit and at any visit after day 7
for PCR analysis. Filter papers were dried and individually stored
in a plastic bag containing silica gel. All filter papers were
subsequently transferred to the Institute of Tropical Medicine
(Antwerp, Belgium) where centralised genotyping was conducted;
deoxyribonucleic acid was purified as described elsewhere [27].
Three polymorphic genetic markers, MSP1, MSP2 and GluRP
were used to distinguish recrudescence from new infections
[28,29]. Recrudescence was defined as at least one identical allele
for each of the three markers in the pre-treatment and post-
treatment samples. New infections were diagnosed when all alleles
for at least one of the markers differed between the two samples.
An independent expert read all gels under blinded conditions
(National Museum of Natural History, Paris, France). For quality
control, 20% of the filter papers were re-analysed and read by an
DHA/PQP in Asia
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District, Tak, Thailand).
Twelve-lead electrocardiograms were recorded at days 0, 2, 7,
28 (if abnormal on day 7), 63 and on the day of any recurrent
parasitaemia that occurred using the CarTouch device with
CarTouch version 1.4.1 software (Cardionics SA, Brussels,
Belgium). The electrocardiogram was viewed during recording
and then transmitted via modem to MDS Pharma Services
Central Telemedicine Department (Paris, France) for interpre-
tation and reporting. The data were analysed using both Bazett’s
(QTc(B)) and Fridericia’s (QTc(F)) correction methods. Electro-
cardiogram results were tabulated as normal, borderline or
prolonged according to gender and age normal ranges (adult
males and children (1–12 years): normal: ,430 msec; border-
line: 430–450 msec; prolonged: .450 msec. Adult females:
normal: ,450 msec; borderline: 450–470 msec; prolonged:
.470 msec).
Blood samples were taken for standard laboratory assessments
of haematology, biochemistry and urinalysis on days 0, 28, 63 (if
abnormal on day 28) and on the day of any recurrent
parasitaemia.
Ethical approval and informed consent
Study staff conducted all interviews with patients, and children’s
parents, in their native language and they explained their rights
under International Conference on Harmonisation-Good Clinical
Practice (ICH-GCP). When obtaining informed consent from
patients the signature of a witness was obtained if patients were
unable to write. Consideration was given to the ethical implications
of the randomisation ratio assigning more patients to receive DHA/
PQP than AS+MQ during the design of the study. As the safety and
tolerability profile of DHA and PQP has been well characterised at
the doses proposed for the present study, it was considered
acceptable to adopt this approach in the present study that would
result in more patients receiving DHA/PQP.
The study protocol was approved by the following ethics
committees: Institutional Ethics Committee, National Institute
of Malaria Research (ICMR), Delhi, India; Goa Medical
College and Hospitals Local Ethics Committee, Goa, India;
Institutional Ethics Committee, Kasturba Medical College,
Mangalore, India; Laos National Ethics Committee for Health
Research (NECHR), National Institute of Public Health,
Vientiane, Laos; Oxford Tropical Research Ethics Committee
(OXTREC), University of Oxford, Headington, United King-
dom; The Ethical Review Committee for Research in Human
Subjects, Ministry of Public Health, Nontaburi, Thailand;
Tropical Medicine Ethics Committee (TMEC), Mahidol
University, Rachathewi District, Bangkok, Thailand. The Food
and Drug Department, Government of Laos PDR, approved
the use of DHA/PQP in that country. The trial was conducted
under the provisions of the Declaration of Helsinki (1964 and
its subsequent amendments up to 2002) and in accordance with
ICH-GCP. A Study Steering Committee, a Data Monitoring
Committee and a Clinical Development Committee were
created prior to the beginning of the trial, and worked
independently to harmonise and monitor the study. The trial
was registered prior to the enrolment of the first patient in the
International Standard Randomised Controlled Trials Register,
number ISRCTN81306618, at http://www.controlled-trials.
com/isrctn/trial/l/0/81306618.html.
Table 1. Rules used to determine patient outcome for the ITT and per protocol populations for the day 63 uncorrected adequate
clinical and parasitological response (ACPR) and polymerase chain reaction (PCR)-corrected ACPR.
Step Event to be assessed ITT Per Protocol
Day-63 uncorrected adequate clinical and parasitological response
1 Informative withdrawal before or at day 63: any reason except lost to follow-up Failure Failure or excluded depending on reason
2 Non-informative withdrawal before or at day 63: lost to follow-up Failure Excluded
3
1 Presence of major protocol violation No effect Excluded
4E T F
2,L C F
3, and LPF
4 in accordance with the WHO criteria Failure Failure
5
1 Data collected on CRF (such as adverse events) raising the suspicion of recurrence of malaria Failure Failure
6
1 Presence of missing parasitaemia at two or more consecutive scheduled visits or presence
of an isolated missing parasitaemia not preceded and followed by a negative parasitaemia
Failure Failure
7
1 Administration of drugs with a known or suspected anti-malaria action as rescue treatment Failure Failure
8
1 Administration of drugs with a known or suspected anti-malaria action as non rescue treatment Failure Excluded
PCR-corrected adequate clinical and parasitological response
9 PCR: non interpretable or missing or not done at or after day 4 Failure Excluded
10 PCR=new infection or uncorrected ACPR=failure for non-falciparum Plasmodia Success Success
11 PCR=recrudescence Failure Failure
ITT = intention to treat.
1Cases in these categories were individually revised at the blind data review meeting. Protocol violations were pre-defined.
2ETF = early treatment failure, defined as development of danger signs (recent convulsions, altered consciousness, lethargy, unable to drink or breast feed, recurrent
vomiting, unable to stand/sit due to weakness) or severe malaria (unarousable coma, repeated convulsions, severe anaemia, respiratory distress, jaundice) on days 0, 1,
2 or 3, and the presence of parasitaemia; parasitaemia with a parasite count on day 2 greater than that on day 0 irrespective of body temperature; parasitaemia on day
3 with fever (temperature $37.5uC); or parasitaemia on day 3$25% of count on day 0.
3LCF = late clinical failure, defined as development of danger signs or severe malaria after day 3 in the presence of parasitaemia or presence of parasitaemia and
temperature $37.5uC (or history of fever) on any day from day 4 to day 63, without previously meeting the criteria of early treatment failure.
4LPF = late parasitological failure, defined as reappearance of parasitaemia after initial clearance between day 7 and day 63 and temperature ,37.5uC, without
previously meeting the criteria of early treatment failure or late clinical failure.
doi:10.1371/journal.pone.0011880.t001
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The statistical analysis was conducted according to a pre-
defined data analysis plan. Three populations were prospectively
planned. The intention-to-treat (ITT) population was defined as
all randomised patients who took at least one dose of study
treatment. The per protocol population was defined as all
randomised patients who were eligible according to the main
(pre-defined) protocol inclusion and exclusion criteria, received at
least 80% of the study medication, underwent the day 63
assessment, took no other anti-malarial drugs (excluding rescue
therapies) and, in the presence of asexual parasite stages on thick
or thin blood smears, had an evaluable PCR test. Patients who
missed visits from day 0 to day 2 were excluded from the per
protocol population. The third population, referred to as modified
ITT, was midway between the two described populations.
Although this was pre-defined as the co-primary population
(together with the per protocol), results in this paper are presented
only for the two most extreme populations, i.e., ITT and per
protocol populations, because these are standard and the findings
were very similar in all populations analysed.
The analysis of the PCR-corrected and uncorrected ACPR (as
defined in Table 1) was based on simple proportions and 97.5%
(one-sided) confidence intervals (CIs) computed on the difference
between these proportions of the test and reference treatments. If
the lower limit of this CI was greater than 25% DHA/PQP could
be considered non-inferior to AS+MQ. The primary time point
was day 63 but this analysis was repeated also at days 42 and 28.
Various sensitivity analyses were carried-out on the primary
endpoint for verifying the robustness of findings towards different
assumptions. These included an analysis where all patients with
missing parasitaemia were treated as failures, an analysis where
patients with new infections as detected by PCR were excluded
and an analysis on two enlarged per protocol populations where all
patients/all early failures ‘‘not receiving at least 80% of study
treatment’’ or ‘‘failing to attend a visit at days 0–2’’ were not
excluded.
The true treatment failures defined in accordance with the
WHO handbook were analysed by means of the survival analysis
(Kaplan-Meier estimates). All sources of uncertainty (i.e. with-
drawals, new infections, patients with PCR results either not
available or indeterminate) were censored. Survival analysis
techniques were also applied to the analysis of time to parasite
clearance and the estimation of the rate of new infections (in the
latter analysis recrudescent infections were censored). For
descriptive purposes, the proportions of early, late and true
treatment failures were also computed as simple rates for each
treatment arm together with the relevant CIs.
By-country heterogeneity in cure rates was assessed by the
Breslow-Day test or by logistic regression, when the former was
not applicable. The study was conducted over two malaria seasons
with different centres working in the two study periods. To
evaluate how the 63-day PCR-corrected cure rates varied across
the cohorts from the two seasons, a logistic regression model was
fitted with cohort and treatment as the explanatory variables. The
treatment by cohort interaction was evaluated as a candidate to
enter this model through a residual score test. All tests for
heterogeneity and interaction were evaluated at the 10%
significance level.
Rates of person-fever-days and person-gametocyte-weeks were
calculated as the number of weeks in which fever was present or
blood slides were positive for gametocytes, respectively, divided by
the number of follow-up weeks and expressed per 100 person-
weeks.
The safety population, which coincides with the ITT popula-
tion, was used for all safety assessments. Adverse events were
coded using the MedDRA dictionary (MedDRA V8.1). Propor-
tions of patients experiencing at least one adverse event were
compared between treatments using the Pearson Chi square test.
To determine the sample size of this study, the PCR-corrected
cure rate at day 63 was estimated to be at least 92% for AS+MQ
in the ITT population using a literature search [30–35]. Expert
opinion was used to define the non-inferiority margin, which was
set at 5%. The planned sample size of 700 in the DHA/PQP arm
and 350 in the AS+MQ arm (1050 patients in total) provided 80%
power to show non-inferiority with a non-inferiority margin of
25% (test minus reference) and a one-sided a level of 2.5%. The
rate of patient attrition in the per protocol population was
expected to be 20% compared with the ITT population, but the
PCR-corrected cure rate was expected to be higher than in the
ITT population (95% in the per protocol population), therefore
the projected power of 80% was maintained also for the analysis
on the per protocol population. When India was included in the
study to increase the speed of recruitment, the total sample size
was increased by 150 patients to ensure that 100 Indian patients
were treated with DHA/PQP, in accordance with Indian
requirements. Consequently, the power of the study exceeded
80%.
Results
Patient disposition and demographic characteristics
One thousand two hundred and thirty-nine patients were
screened, with 769 patients randomised to DHA/PQP and 381
patients randomised to AS+MQ. Figure 1 illustrates the number of
patients completing the study and included in the different study
populations. Sixty-one percent of patients were recruited in
Thailand, 26% in Laos and 13% in India (Table 2).
There were no notable differences in demographic parameters
between treatment arms overall or by country (Table 2). Children
#5 years of age comprised approximately 8% of the study
population, with most of the study population over 18 years of age
(approximately 75%). Median [range] doses received by patients
of the ITT population are presented by age class in Table 3.
One hundred and forty-four patients were excluded from the
per protocol population (Table 2). There were no notable
differences between the treatment arms in the number of patients
excluded from the per protocol population, the most frequent
reasons for exclusion were lost to follow-up before or at day 63 and
PCR missing or indeterminate before or at day 63 (DHA/PQP: 35
patients: AS+MQ: 19 patients).
Primary Endpoint
The analysis of the PCR-corrected cure rate at day 63
confirmed that DHA/PQP was non-inferior to AS+MQ. For the
ITT population, PCR-corrected cure rates were 87.9% for DHA/
PQP and 86.6% for AS+MQ (97.5% CI: .22.87%; Table 4). As
expected, better absolute but comparatively similar results were
obtained for the per protocol population with PCR-corrected cure
rates of 98.7% for DHA/PQP and 97.0% for AS+MQ (97.5% CI:
.20.39%). Sensitivity analyses confirmed these results, with
similar treatment differences between cure rates and relevant CIs
compared with those described above.
Secondary endpoints
Non-inferiority was also proved for the uncorrected cure rates at
day 63: the cure rates were 67.3% in the DHA/PQP arm and
59.6% in the AS+MQ arm (ITT population) with a CI .1.75%.
DHA/PQP in Asia
PLoS ONE | www.plosone.org 5 July 2010 | Volume 5 | Issue 7 | e11880This treatment difference was also statistically significant (Chi-
squared test: p=0.010; Table 4). Similar results were obtained for
the per protocol population (Table 4).
Significantly more patients who received AS+MQ experienced
new infections compared with those receiving DHA/PQP.
Kaplan-Meier estimates for the proportion of patients with new
infection at day 63 were 22.7% for DHA/PQP and 30.3% for
AS+MQ (ITT population; p=0.0042). Similar results were
obtained for the other populations.
Non-inferiority of DHA/PQP versus AS+MQ was also shown
at days 28 and 42 in all study populations (Table 4). On days 28
and 42, in the per protocol population, the PCR-corrected cure
rates defined in Table 1 were significantly greater for DHA/PQP
than AS+MQ (p=0.001 and p=0.031, respectively) while these
differences were not statistically significant in the ITT population
(Table 4).
A logistic regression test to assess by-country heterogeneity in
the PCR-corrected cure rates (evaluated according to Table 1)
showed no significant differences between countries (ITT:
p=0.688; per protocol: p=0.988;). Similar results were obtained
for a Breslow-Day test conducted to assess by-country heteroge-
neity in the uncorrected cure rate (ITT: p=0.896; per protocol:
p=0.728). The 95% (two-sided) CIs at each individual country
level for the PCR-corrected cure rate at day 63 for the per
protocol population are shown in Figure 2A. No effect due to the
cohorts from the two seasons (per protocol: p=0.760) was shown
in this study (Figure 2B shows the relevant CIs) and no difference
was observed by age class (per protocol: p=0.998). Classification
Figure 1. Flow chart of patient disposition.
doi:10.1371/journal.pone.0011880.g001
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years and .18 years (relevant CIs are shown in Figure 2C).
Results in the other populations for country, cohort (season) of
enrolment and age groups were similar.
When the PCR-corrected cure rates were assessed and analysed
according to the WHO recommendations, i.e. as 100 minus the
true treatment failure rate, the results were similar to those in the
PCR-corrected cure rate as defined in Table 1, although cure rates
were always slightly higher. The Kaplan-Meier estimates of the
cure rates were 97.6% (DHA/PQP) versus 96.5% (AS+MQ) in the
ITT population and 98.2% (DHA/PQP) versus 96.8% (AS+MQ)
in the per protocol population. The simple rates of early, late and
true treatment failures on days 63, 42 and 28 are shown in Table 5
together with the relevant CIs.
Kaplan-Meier estimates of median time to parasite clearance
were 2 days for each treatment (ITT population), while the
Kaplan-Meier estimate of the rate of aparasitaemic patients at day
3 (i.e. 24 h after completion of study treatment) was 97.6% for
DHA/PQP and 97.6% for AS+MQ. Similar results were obtained
for the per protocol population. Proportions of afebrile patients
showed very similar profiles to aparasitaemic patients, with profiles
being virtually superimposable. Fever incidence measured in
person-fever-days (per 100 person-days) was similar for DHA/
PQP and AS+MQ: 1065/5315 (20.04%) versus 524/2636
(19.88%), p=0.929 (Table 6; ITT population).
The overall gametocyte prevalence throughout the study (from
day 7 to day 63), measured as person-gametocyte-week rates, was
significantly higher in the DHA/PQP arm in all populations
(DHA/PQP: 76/749, 10.15%; AS+MQ: 18/369, 4.88%;
p=0.003; Table 6, ITT population). However, the treatment
difference for prevalence was not statistically significant from day
35 onwards (Table 6; ITT population).
There were no deaths during the study. In the DHA/PQP
group, there were 12 (1.56%) events judged by the investigator to
be serious, which occurred in 12 patients. Six (0.78%) of these
events were considered by the investigators to be related to DHA/
PQP. These were two cases of anaemia, one from day 7 to day 90,
the other from day 7 to day 35; one viral infection (possibly
Dengue fever) from day 15, fully recovered; and one Wolf
Parkinson White (WPW) syndrome from day 2 to day 90. Wolf
Parkinson White syndrome is a congenital defect of accessory
conduction pathways. Electrocardiograms for this patient were
submitted to two cardiologists to provide expert opinions. Both
considered that the failure to diagnose WPW at baseline could be
attributed to the increased heart rate caused by the patients’ fever
which hid the electrocardiographic characteristics of WPW. Other
events considered serious and related were one convulsion on day
0, and one encephalitis on day 45 which resulted in a left-sided
hemiplegia. The patient was diagnosed with P. falciparum malaria
on day 48, which was treated with i.v. artesunate and oral
mefloquine. The other six (0.8%) serious events were judged
unrelated to DHA/PQP by the investigator: two cases of
pyelonephritis, one case of aspiration pneumonia, and three cases
of P. falciparum malaria. In the AS+MQ group three (0.8%) events
in three patients were judged to be serious and all were judged
related to study treatment: one case of anaemia from day 8, one
Table 2. Baseline characteristics (ITT population).
Variable DHA/PQP AS+MQ
N=767 N=381
Sample size by country; n (%)
Thailand 466 (61) 234 (61)
Laos 200 (26) 98 (26)
India 101 (13) 49 (13)
Gender; n : n
Male : Female 582:185 295:86
Age; years
Mean 6 SD 25.4613.3 25.8613.7
#5 years, n (%) 57 (7) 32 (8)
.5–#12 years, n (%) 68 (9) 31 (8)
.12–#18 years, n (%) 76 (10) 31 (8)
.18–#64 years, n (%) 566 (74) 287 (75)
Weight; kg
Mean 6 SD 44.3615.1 44.6615.1
Race; n (%)
Asian 767 (100) 381 (100)
Presence of fever
n (%) 509 (66) 258 (68)
Temperature in uC
Mean 6 SD 37.9 (1.01) 37.9 (1.02)
Parasite density
Geometric mean 7923.8 9735.4
Haemoglobin; g/L
Normal range (min - max)*: (105–180)
Mean 6 SD 118.2624.5 120.0623.2
n Missing (%) 4 (0.52) 2 (0.52)
n ,100 g/L (%) 162 (21.12) 72 (18.90)
n$100 g/L (%) 601 (78.36) 307 (80.58)
White cells; 610
9/L
Normal range (min - max)*: (3.6–11.0)
Mean 6 SD 6.362.6 6.362.3
Platelets; 610
9/L
Normal range (min - max)*: (140–500)
Mean 6 SD 127.7670.6 124.8665.5
ALT; U/L
Normal range (min - max)*: (0–50)
Mean 6 SD 31.1629.3 32.9641.5
Total bilirubin; mg/dl
Normal range (min - max)*: (0–1.5)
Mean 6 SD 1.1960.85 1.2060.78
Creatinine; mmol/L
Normal range (min - max)*: (0–150.28)
Mean 6 SD 75.5628.7 76.2630.7
Study populations; n (%)
Safety/ITT 767 (99.7) 381 (100.0)
Per protocol 668 (86.9) 336 (88.2)
DHA/PQP = dihydroartemisinin-piperaquine; AS+MQ = artesunate-mefloquine;
SD = standard deviation; Hb = haemoglobin; ALT = alanine aminotransferase.
Table 2. Cont.
*Since the normal laboratory reference ranges vary across centres, the
minimum of the lower limits and the maximum of the upper limits are reported.
doi:10.1371/journal.pone.0011880.t002
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16 to day 31.
Adverse event profiles for DHA/PQP and AS+MQ were very
similar in terms of type and frequency of events and were
consistent with those expected in adult patients with acute malaria.
Most patients in the study experienced adverse events: 69.4%
(532/767) of patients in the DHA/PQP arm and 72.4% (276/381)
of patients in the AS+MQ arm. There was no statistically
significant difference between the treatments in the incidence of
adverse events (p=0.282, Chi-square test). The most frequently
reported adverse events were malaria symptoms, with headache
the most commonly reported (Table 7). The frequencies of
individual adverse events were generally similar between treat-
ments, although the frequencies of nausea, vomiting and dizziness
appeared to be higher in the AS+MQ arm (Table 7). Approxi-
mately 3% of patients in each arm experienced at least one
adverse event related to skin or subcutaneous tissue; the most
frequent was pruritus (DHA/PQP: 17 patients [2.2%]; AS+MQ: 8
patients [2.1%]). One patient in each arm experienced allergic
dermatitis.
As would be expected in patients with malaria, anaemia and
thrombocytopenia were common in each arm, approximate
proportions were 30% for low red blood cells (normal range for
.15 years of age: 3.525.5610
12/L for women and 425.5610
12/
L for men), 50% for low haemoglobin (normal range for .15
years of age: 1102150 g/L for women and 1202160 g/L for
men), and 67% for low platelets (normal range for all ages:
1002300610
9/L). At the end of the study following treatment,
these proportions had decreased to approximately, 20%, 40% and
17%, respectively. There was no apparent difference between
Table 3. Doses (mg/kg) received for each age class (ITT population).
Age range (years) Doses received over 3 days; median [range]
DHA PQP AS MQ
#5 6.7 [1.8–9.2] 53.3 [14.5–73.8] 12.5 [10.7–13.6] 24.0 [21.7–27.8]
.5–#12 7.2 [5.0–10.0] 57.3 [40.0–80.0] 12.5 [10.7–13.2] 25.0 [22.3–26.3]
.12–#18 7.9 [2.9–9.7] 63.3 [22.9–77.8] 12.0 [11.4–12.5] 25.0 [24.2–31.3]
.18–#64 7.1 [2.1–10.0] 56.5 [16.8–80.0] 12.0 [3.9–12.5] 25.0 [0.0–26.5]
DHA = dihydroartemisinin; PQP = piperaquine; AS = artesunate; MQ = mefloquine.
doi:10.1371/journal.pone.0011880.t003
Table 4. Polymerase chain reaction (PCR)-corrected and uncorrected cure rates (ITT and per protocol populations).
DHA/PQP AS+MQ Lower limit of the 97.5% p-value2
% (n) % (n) (one-sided) CI
1
ITT N=767 N=381
Day 63
PCR-corrected cure rate 87.9 (674) 86.6 (330) 22.87 0.544
Uncorrected cure rate 67.3 (516) 59.6 (227) 1.75 0.010
Day 42
PCR-corrected cure rate 90.5 (694) 88.2 (336) 21.56 0.228
Uncorrected cure rate 83.2 (638) 77.4 (295) 0.79 0.019
Day 28
PCR-corrected cure rate 93.7 (719) 91.9 (350) 21.36 0.236
Uncorrected cure rate 92.3 (708) 88.2 (336) 0.37 0.022
Per protocol N=668 N=336
Day 63
PCR-corrected cure rate 98.7 (659/668) 97.0 (326/336) 20.39 0.074
Uncorrected cure rate 75.5 (504/668) 66.4 (223/336) 3.07 0.002
Day 42
PCR-corrected cure rate 99.3 (663) 97.6 (328) 20.12 0.031
Uncorrected cure rate 91.2 (609) 85.4 (287) 1.41 0.006
Day 28
PCR-corrected cure rate 99.9 (667) 97.9 (329) 0.38 0.001
Uncorrected cure rate 98.2 (656) 93.8 (315) 1.68 ,0.001
DHA-PQP = dihydroartemisinin-piperaquine; AS+MQ = artesunate-mefloquine; CI = confidence interval.
1Confidence interval for the difference DHA/PQP minus AS+MQ.
2Chi-squared test.
doi:10.1371/journal.pone.0011880.t004
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over the 63-day follow-up period. In the ITT population, mean
(standard deviation) haemoglobin values on day 0 were 118.7
(24.4) g/L for DHA/PQP and 119.8 (23.4) g/L for AS+MQ. At
day 63, mean (standard deviation) changes from day 0 were 12.8
(22.2) g/L for DHA/PQP and 14.21 (21.2) g/L for AS+MQ.
Figure 2. Ninety-five percent (two-sided) confidence intervals of PCR-corrected cure rates in the ITT population, by country, cohort
of enrolment from the two seasons and age group.
doi:10.1371/journal.pone.0011880.g002
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Other than elevated liver parameters, as might be expected in this
population, there were no relevant changes in biochemistry
parameters.
At baseline, using the QTc(B) method, there was a statistically
significant difference between treatments (Mantel-Haenszel Chi-
square test, p=0.026), with a higher proportion of patients in the
DHA/PQP group having borderline QTc(B) values (16.6% vs.
12.2%; p=0.066). No statistically significant difference between
treatments was observed at baseline for QTc(F) (2.9% for DHA/
PQP vs. 1.6% in AS+MQ). On day 2, there was a statistically
significant difference between treatments (Mantel-Haenszel Chi-
square test p,0.001), with a higher proportion of patients in the
DHA/PQP group having borderline (21.4%; p=0.043) or
prolonged (8.6%; p=0.007) QTc(B) intervals than in the AS+MQ
group (16.3% and 4.2%, respectively). This difference was also
observed for the QTc(F) method: borderline, 13.0% for DHA/
PQP vs. 5.3% for AS+MQ (p,0.001); prolonged, 4.7% for DHA/
PQP vs. 5.3% for AS+MQ (p,0.001). By day 7, there was no
difference between treatments.
The proportion of patients with QTc(B) increase .60 msec from
baseline to day 2 was 0.9% for DHA/PQP vs. 0.8% for AS+MQ
(not significant), and 4.6% for DHA/PQP vs. 2.9% for AS+MQ
when the same increase was assessed with QTc(F) (p,0.001).
However, QTc and QT prolongation were reported as adverse
events by 43 (5.6%) patients in the DHA/PQP group and 16
(4.20%) patients in the AS+MQ group; these were judged by the
investigator to be related to study treatment for 28 (3.65%)
patients in the DHA/PQP group and 13 (3.41%) patients in the
AS+MQ group.
Mean QTc(F)values on day 0 were 387.70 msec for DHA/PQP
and 385.54 msec for AS+MQ. Mean increases from baseline to day
2 were 22.93 msec and 14.65 msec, respectively. This difference
between treatments was statistically significant (p ,0.001). On day
7, the mean increase from day 0 for DHA/PQP had fallen to 10.47
msec with the value for AS+MQ being 13.39 msec; this difference
was not statistically significant (p=0.075).
Discussion
In this study conducted in Thailand, Laos and India, we have
shown that both the DHA/PQP and AS+MQ treatment
Table 5. Early, late and true treatment failure rates
1 as
defined by WHO (ITT and per protocol populations).
DHA/PQP AS+MQ 95% CI
%( n ) %( n )
ITT
Early treatment failures 0.52 (4) 0.26 (1) 20.46, 0.98
Day 63
Late treatment failures 13.17 (101) 14.96 (57) 26.10, 2.52
True treatment failures 2.09 (16) 2.62 (10) 22.44, 1.36
Day 42
Late treatment failures 5.74 (44) 9.71 (37) 27.37, 20.58
True treatment failures 1.17 (9) 2.10 (8) 22.56, 0.70
Day 28
Late treatment failures 1.17 (9) 5.25 (20) 26.44, 21.71
True treatment failures 0.65 (5) 1.84 (7) 22.65, 0.28
Per protocol
Early treatment failures 0 0.30 (1) 20.89, 0.28
Day 63
Late treatment failures 12.87 (86) 15.48 (52) 27.23, 2.02
True treatment failures 1.65 (11) 2.98 (10) 23.39, 0.73
Day 42
Late treatment failures 5.84 (39) 9.82 (33) 27.63, 20.34
True treatment failures 0.75 (5) 2.38 (8) 23.39, 0.12
Day 28
Late treatment failures 0.90 (6) 4.76 (16) 26.25, 21.48
True treatment failures 0.15 (1) 2.08 (7) 23.49, 20.38
1The rates reported in this table are simple rates.
doi:10.1371/journal.pone.0011880.t005
Table 6. Prevalence of gametocytes and fever according to
day of follow-up (ITT population).
DHA/PQP AS+MQ p-value1
N=767 N=381
n/N (%) n/N (%)
Gametocyte prevalence
2
Day 7 59/749 (7.88) 15/369 (4.07) 0.016
Day 14 30/742 (4.04) 3/365 (0.82) 0.003
Day 21 16/733 (2.18) 0/362 0.005
Day 28 9/722 (1.25) 0/353 0.035
Day 35 1/715 (0.14) 0/339 1.000
Day 42 1/692 (0.14) 0/328 1.000
Day 49 2/666 (0.30) 0/316 1.000
Day 56 1/651 (0.15) 1/312 (0.32) 0.543
Day 63 1/623 (0.16) 2/301 (0.66) 0.249
Overall (from day 7
up to day 63)
76/749 (10.15) 18/369 (4.88) 0.003
Person-gametocye-weeks
3
(/100 person-weeks)
130/6420 (2.02) 23/3108 (0.74) 0.014
Fever prevalence
2
Day 0 509/767 (66.36) 258/381 (67.72) 0.646
Day 1 244/767 (31.81) 129/381 (33.86) 0.486
Day 2 80/765 (10.46) 44/379 (11.61) 0.555
Day 3 51/764 (6.68) 21/379 (5.54) 0.457
Day 7 40/753 (5.31) 16/373 (4.29) 0.458
Overall (from day 0
up to day 7)
566/767 (73.79) 298/381 (78.22) 0.102
Person-fever-days
4
(/100 person-days)
1065/5315 (20.03) 524/2636 (19.88) 0.929
DHA/PQP = dihydroartemisinin-piperaquine; AS+MQ = artesunate-mefloquine.
1Pearson Chi-square or Fisher’s exact test, as appropriate.
2Calculated, at a given time, as number of patients with gametocytes, or fever
$37.5uC,atthattimedividedbythenumberofpatientshavingreached thattime.
3Calculated as number of weeks in which blood slides were positive for
gametocytes during the whole study (up to a maximum duration of 70 days)
divided by the number of all follow-up weeks and expressed per 100 person-
weeks. Withdrawal patients were analysed up to the date of withdrawal recorded
in theefficacy dataset evenif they performed additionalgametocyte assessments.
4Calculated as number of days in which temperature was greater or equal to
37.5 during the first study week divided by the number of all first follow-up
weeks and expressed per 100 person-days. Withdrawal patients were analysed
up to the date of withdrawal recorded in the efficacy dataset even if they
performed additional assessments for temperature.
doi:10.1371/journal.pone.0011880.t006
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The day-63 PCR-corrected cure rates (as defined in Table 1) were
87.9% for DHA/PQP and 86.6% for AS+MQ in the ITT
population and 98.7% for DHA/PQP and 97.0% for AS+MQ in
the per protocol population. In terms of this primary outcome
variable, DHA/PQP was non-inferior to AS+MQ. Review of the
data by country found no differences between the primary
outcome measures, further confirming that DHA/PQP was
similarly active against the P. falciparum found in India, Laos and
Thailand, relative to AS+MQ. The PCR-corrected cure rates
observed for DHA/PQP in this study were in line with the day-63
PCR-corrected cure rates noted in a previous study conducted in
Thailand [32], day-42 rates observed in Myanmar (Burma) [11]
and Laos [36] and day-28 cure rates observed in Cambodia [8].
Likewise, PCR-corrected cure rates for AS+MQ were also similar
to previous studies of AS+MQ conducted in Thailand [10,37–39],
Laos [40,41] and India [38], which generally showed rates ranging
from approximately 95% to 100% in the per protocol population.
Polymerase chain reaction-corrected cure rates for both DHA/
PQP and AS+MQ exceeded 95% on days 28, 42 and 63. The
95% threshold on day 28 is the level the WHO recommend for
adoption of a new treatment [14].
This is the first study of the use of DHA/PQP in the Indian
population, with 101 patients receiving the combination. Although
this was only 13% of the patients in our study, we feel that it
provides sufficient numbers to enable an initial assessment of the
response to DHA/PQP in communities in Assam, Goa and
Mangalore. India, Thailand and Laos have different backgrounds
in terms of parasite transmission, resistance and seasonality of
infection, yet a heterogeneity analysis showed no statistically
significant difference in the relative responses to the two
treatments between India and the other countries in the study.
Indian communities that we sampled in this study had notable
levels of chloroquine resistance, with historical site records
showing treatment failure rates for chloroquine treatment ranging
from 32% to 67% (28 days of follow-up). The sites in Laos and
Thailand were also in regions with high levels of chloroquine
resistance [22,24,25,42]. Based on the structural similarities of
chloroquine and PQP, there was the potential for cross-resistance
and a low response to DHA/PQP may have been expected.
However, the DHA/PQP combination appeared to be unaffected
by any potential cross-resistance and PCR-corrected cure rates
were similar for India (96.5%), Thailand (96.6%) and Laos
(98.0%).
The DHA/PQP combination exerted a significant post-
treatment prophylactic effect in this study. This is supported by,
first, significant reductions in the incidence of new infections for
DHA/PQP compared with AS+MQ and second, by higher
uncorrected cure rates in the DHA/PQP arm than AS+MQ, as
the uncorrected cure rate endpoint includes new infections as well
as recurrence of infection. This effect is thought to be modulated
by levels of drug remaining in the blood because of the long half-
life of PQP. The post-treatment prophylaxis was significantly
better for DHA/PQP reflecting the differential terminal half lives
of PQP and MQ (4–5 weeks for PQP and 14 days for MQ). The
extended post-treatment prophylactic effect is of particular
importance in countries with a high risk of new infection and
can also reduce the risk of anaemia by allowing patients more time
for haematological recovery between infections. The DHA/PQP
combination, like all ACTs, rapidly reduces parasite biomass in
the patient through the brief yet potent activity of DHA (the
artemisinin component). Subsequent removal of uncleared
parasites is achieved by the less active but more slowly eliminated
partner drug; in this case PQP with a half-life of 4–5 weeks
[43,44]. The slightly shorter half-life of MQ [45] may explain the
difference observed in the post-treatment prophylactic effect of the
two regimens. The DHA/PQP regimen has previously been
shown to exert a superior post-treatment prophylactic effect to
another ACT, artemether-lumefantrine [46]. Overall gametocyte
prevalence was significantly higher in the DHA/PQP arm than
AS+MQ. The viability of gametocytes remaining post-treatment
was not assessed in this study. One potential point of interest for
future studies would be to determine whether the viability of any
remaining gametocytes is compromised by treatment with DHA/
PQP.
Although formal statistical comparison of the tolerability profile
of the two combinations was not planned or conducted, some
individual adverse events appeared to be reported more frequently
in patients receiving AS+MQ than those receiving DHA/PQP.
Mefloquine has been linked with adverse events of gastrointestinal
and central nervous system origin. In this study, the frequency of
reporting of nausea, vomiting and dizziness was 2–3 fold higher in
the AS+MQ arm than the DHA/PQP arm. Vomiting soon after
dosing is an important determinant of treatment efficacy as
attaining and maintaining effective systemic levels of anti-malarial
drugs is essential to disease outcome. This is of particular
importance where there are powerful influences on adherence to
dosing regimens. Increases in QTc(F) interval were seen for both
DHA/PQP and AS+MQ after the start of treatment, but a
statistically significant increase from baseline was observed in QTc
interval for DHA/PQP relative to AS+MQ on day 2. An
important element in assessing the clinical importance of QTc
prolongation is the extent of change from baseline: an increase in
QTc interval from baseline of .60 msec could be clinically
Table 7. Most frequently reported adverse events (.5% of
either treatment arm; ITT population).
Event DHA/PQP AS+MQ Chi-Square
N=767 N=381 p-value
n( % ) n( % )
Headache 138 (18.0) 77 (20.2) 0.3644
Malaria
1 111 (14.5) 86 (22.6) 0.0006
P. falciparum infection 103 (13.4) 58 (15.2) 0.4097
Pyrexia 81 (10.6) 43 (11.3) 0.7092
Eosinophilia 65 (8.5) 38 (10.0) 0.4026
Cough 60 (7.8) 37 (9.7) 0.2786
Anaemia 55 (7.2) 25 (6.6) 0.7027
Myalgia 46 (6.0) 22 (5.8) 0.8801
Arthralgia 42 (5.5) 21 (5.5) 0.9799
Prolonged QTc interval 41 (5.4) 16 (4.2) 0.3999
Abdominal pain 40 (5.2) 20 (5.3) 0.9804
Asthenia 38 (5.0) 29 (7.6) 0.0705
Anorexia 38 (5.0) 21 (5.5) 0.6871
Nausea 22 (2.9) 26 (6.8) 0.0016
Vomiting 19 (2.5) 24 (6.3) 0.0013
Dizziness 11 (1.4) 24 (6.3) ,.0001
DHA/PQP = dihydroartemisinin-piperaquine; AS+MQ = artesunate-
mefloquine.
1Reporting of malaria as an adverse event was not complete in this study. Some
study centres chose not to report malaria as it was known that to enter the
study all patients had to have Plasmodium falciparum infection.
doi:10.1371/journal.pone.0011880.t007
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arrhythmias in non-cardiovascular indications (ICH E14 guide-
line). There was a statistically significant treatment difference for
the proportion of patients with such an increase in QTc(F), while
no treatment differences were observed for the same increase in
QTc(B) and for the incidence of cardiac events. Finally, by day 7
there were no significant differences between treatments. Based on
our results, it is difficult to attribute a particular clinical relevance
to the QTc increase observed with DHA/PQP. In fact, it is
expected that malaria shortens the QT interval during the acute
illness, leading to increases after the start of treatment. Most
studies of antimalarial drugs report some transient prolongation of
the QT interval in the days after the start of treatment [47]. No
warnings were found in the literature about QTc prolongation
with DHA/PQP.
For patients to access DHA/PQP via public sector healthcare
systems, this fixed dose combination requires regulatory approval.
One requirement for registration is that the formulation must be
manufactured according to GMP. This study was conducted as
one of a series of pharmacokinetic and ICH-GCP-compliant
randomised, controlled trials at sites across Africa and South East
Asia using DHA/PQP manufactured according to GMP.
In conclusion, the fixed dose DHA/PQP combination tablet in
this study emerged as a highly efficacious treatment for P.
falciparum malaria. The effects were observed across the three
Asian countries in which the study was conducted, with no country
effect. The combination of DHA/PQP provided greater protec-
tion against new infections than AS+MQ. Results from this study
indicate that, although there may be evidence that suggests that
the overall efficacy of ACTs may be falling, DHA/PQP can play
an important role in, possibly, a new policy of multiple first-line
treatments of uncomplicated falciparum malaria.
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